Biocryst (BCRX) Falls After Company Left Out of CDC's Recommened Flu Drugs
September 8, 2009 3:01 PM EDT
Shares Biocryst Pharmaceuticals (Nasdaq: BCRX) fell mid-day after the company's peramivir wasn't on an updated list of flu treatment guidelines released by the CDC.
The CDC is recommending treatment with Roche's oseltamivir (Tamiflu) or GlaxoSmithKline's (NYSE: GSK) zanamivir (Relenza) for all persons with suspected or confirmed influenza requiring hospitalization.
Shares of BCRX are down down 5.9% in late afternoon trading
BTA Price at posting:
$2.12 Sentiment: LT Buy Disclosure: Held
